Contents

Preface
Contributors

PART I  INTRODUCTION

1. Basic Principles of Antisense Technology
   Stanley T. Crooke

2. Medicinal Chemistry of Antisense Oligonucleotides
   P. Dan Cook

3. Analytical Methods for Antisense Drugs
   Janet M. Leeds and Lendell L. Cummins

4. A Role for Antisense Technology in the Discovery of Highly Specific and Versatile Signal Transduction Inhibitors
   Brett P. Monia, Erich Koller, and William A. Gaarde

5. Methods of Selecting Sites in RNA for Antisense Targeting
   Susan M. Freier
PART II PROPERTIES OF PHOSPHOROTHIOATE OLIGONUCLEOTIDES

6. Pharmacokinetic Properties in Animals
   Richard S. Geary, Rosie Z. Yu, Janet M. Leeds, Michael V. Templin, Tanya A. Watanabe, Scott P. Henry, and Arthur A. Levin

7. Suborgan Pharmacokinetics
   Rosanne M. Crooke and Mark J. Graham

8. Pharmacokinetic Properties in Humans
   Rosie Z. Yu, Steven L. Schoenfeld, Richard S. Geary, Tanya A. Watanabe, and Arthur A. Levin

9. Toxicity of Antisense Oligonucleotides
   Arthur A. Levin, Scott P. Henry, David Monteith, and Michael V. Templin

10. Clinical Safety of Phosphorothioate Oligodeoxynucleotides
    F. Andrew Dorr, Josephine G. Glover, and T. Jesse Kwoh

11. General Pharmacology of Phosphorothioate Oligodeoxynucleotides
    C. Frank Bennett

PART III PROPERTIES OF ADVANCED NOVEL CLINICAL CLASSES OF OLIGONUCLEOTIDES

12. Pharmacology of 2′-O-(2-Methoxy)ethyl-Modified Antisense Oligonucleotides
    Nicholas M. Dean, Madeline Butler, Brett P. Monia, and Muthiah Manoharan

13. LNA (Locked Nucleic Acid)
    Jesper Wengel

14. Antisense Properties of Peptide Nucleic Acid (PNA)
    Uffe Koppelhus and Peter E. Nielsen
15. Phosphorodiamidate Morpholino Oligomers
   *Patrick Iversen*
   
16. Oligonucleotide Conjugates in Antisense Technology
   *Muthiah Manoharan*
   
17. Immune Stimulation by Oligonucleotides
   *Arthur M. Krieg*
   
18. Pre-mRNA Splicing as a Target for Antisense Oligonucleotides
   *Ryszard Kole* and *Danielle Mercatante*
   
19. Application of Antisense Oligonucleotides to the Study of CNS
    Protein Function
   *Siew Peng Ho*
   
20. Antisense Approach to Isoform-Specific Blockade of
    Acetylcholinesterase
   *Hermona E. Soreq* and *Shlomo Seidman*
   
21. Serine/Threonine Protein Phosphatases
   *Richard E. Honkanen*
   
22. Pharmacological Activities of Antisense Drugs: Inflammatory
    Diseases
   *James G. Karras, Kathleen J. Myers, and Brenda F. Baker*
   
23. Respirable Antisense Oligonucleotides (RASONs)
   *Jonathan W. Nyce*
   
24. Combined Antisense Therapy and Chemotherapy in Animal
    Models
   *Dan Mercola*
   
25. Antisense Oligodesoxynucleotide Strategies in Renal and
    Cardiovascular Disease
   *Hermann Haller, Christian Maasch, Duska Dragun, Maren
    Wellner, and Friedrich C. Luft*
   
26. The Development of Antisense Oligonucleotides as Antivirals
   *Lisa R. Grillone*
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Author(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>27</td>
<td>Clinical Activities in Patients with Solid Tumors or Lymphoma</td>
<td>Jon T. Holmlund</td>
<td>739</td>
</tr>
<tr>
<td>28</td>
<td>Nucleic Acid Therapeutics for the Treatment of Human Leukemia</td>
<td>Alan M. Gewirtz</td>
<td>761</td>
</tr>
<tr>
<td>29</td>
<td>ISIS 2302, an Antisense Inhibitor of Intercellular Adhesion Molecule 1 (ICAM-1)</td>
<td>William R. Shanahan, Jr.</td>
<td>773</td>
</tr>
<tr>
<td>30</td>
<td>New Routes and Novel Formulations for Delivery of Antisense Oligonucleotides</td>
<td>Gregory E. Hardee, Susan P. Weinbach, and Lloyd G. Tillman</td>
<td>795</td>
</tr>
<tr>
<td>31</td>
<td>DNA-Binding Molecules</td>
<td>Roland W. Bürli and Heinz E. Moser</td>
<td>833</td>
</tr>
<tr>
<td>32</td>
<td>Targeted Genome Modification via Triple Helix Formation</td>
<td>Margaret A. Macris and Peter M. Glazer</td>
<td>859</td>
</tr>
<tr>
<td>33</td>
<td>Intracellular Ribozyme Applications</td>
<td>John J. Rossi</td>
<td>887</td>
</tr>
</tbody>
</table>

*Index* 907